Letter

Quadrivalent HPV vaccine

Wider cost benefits of vaccine

BMJ 2010; 341 doi: 10.1136/bmj.c4455 (Published 19 August 2010)
Cite this as: BMJ 2010;341:c4455

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Colm O’Mahony, consultant in genitourinary medicine and HIV1,
  2. Peter Greenhouse2,
  3. Angela Robinson3,
  4. Chris Sonnex4
  1. 1Department of Sexual Health (GUM), Countess of Chester Hospital, Chester CH2 1UL
  2. 2Bristol Sexual Health Centre, Bristol BS2 0JD
  3. 3Mortimer Market Centre, London WC1E 6JB
  4. 4Addenbrooke’s Hospital, Cambridge CB2 2QQ
  1. colm.omahony{at}hotmail.co.uk

    The FUTURE Study Group’s results confirm the benefit to women of vaccinating against human papillomavirus (HPV) types 16 and 18 and emphasise the value of including HPV-6 and HPV-11 in any vaccine programme.1 HPV-6 and HPV-11 cause almost all condylomatas and a large proportion of cases of low grade vulval, vaginal, and cervical intraepithelial …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular